<DOC>
	<DOCNO>NCT00731653</DOCNO>
	<brief_summary>The objective study allow patient participate precursor study BCI-024 combination BCI-049 versus placebo BCI-024 alone ( Protocol # CBM-IT-01 ) receive 6 week open-label treatment increase dose BCI-024 combination increase dose BCI-049 . The safety tolerability high dose combination evaluate , treatment effect reduce symptom depression patient MDD .</brief_summary>
	<brief_title>Open Label Extension Assessing Tolerability BCI-024 Combination With BCI-049 Patients With Major Depressive Disorder ( MDD )</brief_title>
	<detailed_description>Up approximately 120 adult outpatient meet study 's inclusion exclusion criterion may enrol study .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Subjects willing provide write informed consent complete participation Protocol CBMIT01 eligible study . Eligible subject demonstrate compliance CBMIT01 's protocol requirement . Subjects complete participation Protocol CBMIT01 eligible study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>depression</keyword>
	<keyword>combination</keyword>
</DOC>